# Provectus Biopharmaceuticals, Inc.: financial statements, quarterly

PVCT · OTC · CIK 315545 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/pvct.md) · [Financials](/companies/pvct/financials.md) · [Filings](/companies/pvct/filings.md) · [Insiders](/companies/pvct/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/pvct/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $k | [69.7](/filings/0001493152-24-044720.md) | [121 d](/filings/0001641172-25-000993.md) | [238](/filings/0001641172-25-010273.md) | [255](/filings/0001641172-25-023864.md) | [110](/filings/0001493152-25-022229.md) | [14.3 d](/filings/0001493152-26-012726.md) | [279](/filings/0001493152-26-022950.md) | [57.5](/filings/0001493152-26-037671.md) | [0.0 d](/filings/0001493152-25-022229.md) | [0.0 d](/filings/0001493152-26-012726.md) | not reported | not reported |
| Research and development | $k | [351](/filings/0001493152-24-044720.md) | [416 d](/filings/0001641172-25-000993.md) | [556](/filings/0001641172-25-010273.md) | [473](/filings/0001641172-25-023864.md) | [414](/filings/0001493152-25-022229.md) | [608 d](/filings/0001493152-26-012726.md) | [403](/filings/0001493152-26-022950.md) | [881](/filings/0001493152-26-037671.md) | [346](/filings/0001493152-25-022229.md) | [268 d](/filings/0001493152-26-012726.md) | [333](/filings/0001493152-26-022950.md) | [131](/filings/0001493152-26-037671.md) |
| Operating income | $k | [(714)](/filings/0001493152-24-044720.md) | [(605) d](/filings/0001641172-25-000993.md) | [(447)](/filings/0001641172-25-010273.md) | [(795)](/filings/0001641172-25-023864.md) | [(956)](/filings/0001493152-25-022229.md) | [(2,335) d](/filings/0001493152-26-012726.md) | [(1,098)](/filings/0001493152-26-022950.md) | [(1,801)](/filings/0001493152-26-037671.md) | [(1,276)](/filings/0001493152-25-022229.md) | [(1,120) d](/filings/0001493152-26-012726.md) | [(1,248)](/filings/0001493152-26-022950.md) | [(939)](/filings/0001493152-26-037671.md) |
| Interest expense | $k | not reported | not reported | not reported | not reported | not reported | not reported | [63.7](/filings/0001493152-26-022950.md) | [51.4](/filings/0001493152-26-037671.md) | not reported | not reported | [53.0](/filings/0001493152-26-022950.md) | [50.3](/filings/0001493152-26-037671.md) |
| Net income | $k | [(776)](/filings/0001493152-24-044720.md) | [(663) d](/filings/0001641172-25-000993.md) | [(504)](/filings/0001641172-25-010273.md) | [(847)](/filings/0001641172-25-023864.md) | [(1,014)](/filings/0001493152-25-022229.md) | [(2,367) d](/filings/0001493152-26-012726.md) | [(1,140)](/filings/0001493152-26-022950.md) | [(1,814)](/filings/0001493152-26-037671.md) | [(1,311)](/filings/0001493152-25-022229.md) | [(1,165) d](/filings/0001493152-26-012726.md) | [(1,290)](/filings/0001493152-26-022950.md) | [(983)](/filings/0001493152-26-037671.md) |
| Diluted EPS | $ per share | [0.00](/filings/0001493152-24-044720.md) | not reported | [0.00](/filings/0001641172-25-010273.md) | [0.00](/filings/0001641172-25-023864.md) | [0.00](/filings/0001493152-25-022229.md) | not reported | [0.00](/filings/0001493152-26-022950.md) | [0.00](/filings/0001493152-26-037671.md) | [0.00](/filings/0001493152-25-022229.md) | not reported | [0.00](/filings/0001493152-26-022950.md) | [0.00](/filings/0001493152-26-037671.md) |
| Basic EPS | $ per share | [0.00](/filings/0001493152-24-044720.md) | not reported | [0.00](/filings/0001493152-24-019184.md) | [0.00](/filings/0001641172-25-023864.md) | [0.00](/filings/0001493152-25-022229.md) | not reported | [0.00](/filings/0001493152-26-022950.md) | [0.00](/filings/0001493152-26-037671.md) | [0.00](/filings/0001493152-25-022229.md) | not reported | [0.00](/filings/0001493152-26-022950.md) | [0.00](/filings/0001493152-26-037671.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpenseNonoperating
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $k | [367](/filings/0001493152-24-044720.md) | [76.6](/filings/0001641172-25-000993.md) | [18.0](/filings/0001641172-25-010273.md) | [29.6](/filings/0001641172-25-023864.md) | [187](/filings/0001493152-25-022229.md) | [307](/filings/0001493152-26-012726.md) | [390](/filings/0001493152-26-022950.md) | [386](/filings/0001493152-26-037671.md) | [72.5](/filings/0001493152-25-022229.md) | [251](/filings/0001493152-26-012726.md) | [224](/filings/0001493152-26-022950.md) | [1,157](/filings/0001493152-26-037671.md) |
| Current assets | $k | [1,592](/filings/0001493152-23-040856.md) | [1,365](/filings/0001641172-25-000993.md) | [1,009](/filings/0001493152-24-019184.md) | [800](/filings/0001493152-24-031524.md) | [760](/filings/0001493152-24-044720.md) | [977](/filings/0001493152-26-012726.md) | [649](/filings/0001641172-25-010273.md) | [568](/filings/0001641172-25-023864.md) | [278](/filings/0001493152-25-022229.md) | [568](/filings/0001493152-26-037671.md) | [460](/filings/0001493152-26-022950.md) | [1,369](/filings/0001493152-26-037671.md) |
| Total assets | $k | [1,690](/filings/0001493152-23-040856.md) | [1,449](/filings/0001641172-25-000993.md) | [1,079](/filings/0001493152-24-019184.md) | [856](/filings/0001493152-24-031524.md) | [802](/filings/0001493152-24-044720.md) | [1,006](/filings/0001493152-26-012726.md) | [666](/filings/0001641172-25-010273.md) | [722](/filings/0001641172-25-023864.md) | [420](/filings/0001493152-25-022229.md) | [698](/filings/0001493152-26-037671.md) | [578](/filings/0001493152-26-022950.md) | [1,474](/filings/0001493152-26-037671.md) |
| Current liabilities | $k | [9,172](/filings/0001493152-23-040856.md) | [9,017](/filings/0001641172-25-000993.md) | [8,516](/filings/0001493152-24-019184.md) | [8,370](/filings/0001493152-24-031524.md) | [6,225](/filings/0001493152-24-044720.md) | [6,975](/filings/0001493152-26-012726.md) | [5,735](/filings/0001641172-25-010273.md) | [6,493](/filings/0001641172-25-023864.md) | [6,472](/filings/0001493152-25-022229.md) | [6,897](/filings/0001493152-26-037671.md) | [7,242](/filings/0001493152-26-022950.md) | [7,707](/filings/0001493152-26-037671.md) |
| Total liabilities | $k | [9,209](/filings/0001493152-23-040856.md) | [9,042](/filings/0001641172-25-000993.md) | [8,529](/filings/0001493152-24-019184.md) | [8,370](/filings/0001493152-24-031524.md) | [6,225](/filings/0001493152-24-044720.md) | [6,975](/filings/0001493152-26-012726.md) | [5,735](/filings/0001641172-25-010273.md) | [6,597](/filings/0001641172-25-023864.md) | [6,587](/filings/0001493152-25-022229.md) | [7,000](/filings/0001493152-26-037671.md) | [7,308](/filings/0001493152-26-022950.md) | [7,761](/filings/0001493152-26-037671.md) |
| Short-term borrowings | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $k | [(7,519)](/filings/0001493152-24-044720.md) | [(7,593)](/filings/0001641172-25-000993.md) | [(7,450)](/filings/0001493152-24-044720.md) | [(7,513)](/filings/0001493152-24-044720.md) | [(5,423)](/filings/0001493152-24-044720.md) | [(5,959)](/filings/0001493152-26-012726.md) | [(5,103)](/filings/0001641172-25-010273.md) | [(5,871)](/filings/0001641172-25-023864.md) | [(6,151)](/filings/0001493152-25-022229.md) | [(6,299)](/filings/0001493152-26-037671.md) | [(6,725)](/filings/0001493152-26-022950.md) | [(6,275)](/filings/0001493152-26-037671.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Short-term borrowings: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [(769) d](/filings/0001493152-24-044720.md) | [(561) d](/filings/0001641172-25-000993.md) | [(1,044)](/filings/0001641172-25-010273.md) | [(763) d](/filings/0001641172-25-023864.md) | [(565) d](/filings/0001493152-25-022229.md) | [(912) d](/filings/0001493152-26-012726.md) | [(1,093)](/filings/0001493152-26-022950.md) | [(523) d](/filings/0001493152-26-037671.md) | [(840) d](/filings/0001493152-25-022229.md) | [(870) d](/filings/0001493152-26-012726.md) | [(358)](/filings/0001493152-26-022950.md) | [(358) d](/filings/0001493152-26-037671.md) |
| Capital expenditure | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: not reported

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [419](/filings/0001493152-23-040856.md) | [419](/filings/0001493152-24-019184.md) | [419](/filings/0001493152-24-031524.md) | [420](/filings/0001493152-24-044720.md) | [420](/filings/0001641172-25-010273.md) | [420](/filings/0001641172-25-023864.md) | [420](/filings/0001493152-25-022229.md) | [420](/filings/0001493152-26-022950.md) | [420](/filings/0001493152-26-037671.md) | [420](/filings/0001493152-25-022229.md) | [420](/filings/0001493152-26-022950.md) | [420](/filings/0001493152-26-037671.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 420,279,879 at 2026-08-11, from the cover of the [10-Q filed 2026-08-13](/filings/0001493152-26-037671.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:21 ET. No prices; not investment advice.